Phospholipase D1-Promoted Release of Tissue Plasminogen Activator Facilitates Neurite Outgrowth

Yan Zhang, Yasunori Kanaho, Michael A. Frohman, and Stella E. Tsirka

Temporal lobe epilepsy (TLE) is the most common form of epilepsy, affecting ~1–2% of the population. Seizure events resulting from TLE are characterized by aberrant hippocampal mossy fiber sprouting and plastic responses that affect brain function. Seizure susceptibility is modulated by the enzyme tissue plasminogen activator (tPA), the normal physiological role of which includes promotion of synaptic reorganization in the mossy fiber pathway by initiating a proteolytic cascade that cleaves extracellular matrix components and influences neurite extension. tPA is concentrated at and selectively secreted from growth cones during excitatory events. However, the mechanisms underlying tPA release during seizure-induced synaptogenesis are not well understood. We examine here potential roles for the signaling enzyme phospholipase D1 (PLD1), which promotes regulated exocytosis in non-CNS cell types, and which we previously demonstrated increases in expression in hippocampal neurons during seizure-induced mossy fiber sprouting. We now show that overexpression of wild-type PLD1 in cultured neurons promotes tPA release and tPA-dependent neurite extension, whereas overexpression of an inactive PLD1 allele or pharmacological inhibition of PLD1 inhibits tPA release. Similarly, viral delivery of wild-type PLD1 into the hippocampus facilitates tPA secretion and mossy fiber sprouting in a seizure-inducing model, whereas the inactive PLD1 allele inhibits tPA release and elicits blunted and abnormal mossy fiber extension similar to that observed for tPA−/− mice. Together, these findings suggest that PLD1 functions endogenously to regulate tPA−/− secretion and thus mossy fiber extension in the setting of elevated neuronal stimulation, such as that seen in TLE.

Key words: serine protease; phospholipids; neuroplasticity; secretion; hippocampus; mossy fiber

Introduction

Temporal lobe epilepsy is a common type of epilepsy (Engel et al., 1997). After epileptogenic injuries, dentate granule cell axons [mossy fibers (MF)] sprout and form new synaptic connections (Parent and Lowenstein, 1997; Represa and Ben-Ari, 1997). This aberrant synaptogenesis generates recurrent excitatory circuits that affect brain functioning (Buckmaster et al., 2004). Tissue plasminogen activator (tPA) is an extracellular serine protease involved in the pathological excitiation of glutamate receptor-expressing neurons (Qian et al., 1993; Nicole et al., 2001). tPA activates plasminogen to plasmin by proteolytic cleavage; plasmin degrades extracellular matrix (ECM) components such as chondroitin sulfate proteoglycans and influences neurite extension, sprouting, and synaptic reorganization in the MF pathway (Wu et al., 2000). tPA is focally concentrated at and selectively secreted from neuronal growth cones during excitation (Krytosek and Seeds, 1981; Pittman, 1985; Verrall and Seeds, 1988).

However, the molecular mechanisms that regulate tPA release from the growth cone after epileptiform events await elucidation. The signaling enzyme phospholipase D (PLD), which hydrolyzes phosphatidylcholine (PC) to generate phosphatidic acid (PA), plays important roles in exocytosis, phagocytosis, membrane trafficking, and cytoskeletal dynamics (Liscovitch et al., 2000; Cockcroft, 2001; McDermott et al., 2004). Two mammalian PLD genes, PLD1 and PLD2, exist and have been characterized at the molecular level (Frohman et al., 1999). Both enzymes are upregulated in response to extracellular agonist signals, neurotransmitters, growth factors, hormones, and cytokines. PLD1 has been linked to regulation of secretion and secretory granule exocytosis (Chen et al., 1997; Vitale et al., 2001; Choi et al., 2002; Hughes et al., 2004), whereas PLD2 plays a more obvious role in regulation of cell morphology and endocytosis (Colley et al., 1997; Honda et al., 1999; Du et al., 2004).

In culture and in vivo studies have suggested a role for this enzyme in the modulation of neurite outgrowth. PLD expression and activity have been reported to increase during neuronal differentiation of the rat pheochromocytoma cell PC12 and the immortalized mouse hippocampal stem cell HiB5 (Hayakawa et al., 1999; Min et al., 2001; Sung et al., 2001), and blocking PLD activation significantly inhibited neurite outgrowth. PLD1 and PLD2 have been reported to be expressed in PC12 cells (Hayakawa et al., 1999); however, the pattern of expression differs in different sub-
lines (Gibbs and Meier, 2000). Establishing relevance for the in vivo setting, we found in mice that neurons express PLD1 and astrocytes express PLD2. Both proteins undergo expression up-regulation during hippocampal MF sprouting (Zhang et al., 2004). These findings prompted us to investigate the role of neuronally expressed PLD1 on neurite growth and the underlying mechanism through which it functions.

In this study, we demonstrate that overexpression of wild-type PLD1 enhances tPA secretion both in cultured primary hippocampal neurons and in the brain, whereas overexpression of catalytically inactive PLD1 or pharmacological diversion of PLD activity is inhibitory. We also report that overexpression of wild-type PLD1 potentiates hippocampal MF outgrowth, whereas competitive inhibition of endogenous PLD1 by overexpression of the inactive allele blunts MF outgrowth, identifying a new regulatable step in the process.

Materials and Methods

Generation of Sindbis pseudovirions. Sindbis pseudovirions were generated using the Sindbis Expression kit. cDNA fragments encoding wild-type PLD1 and the catalytic-inactive PLD1 (K898R) open reading frames were subcloned into the Sindbis virus backbone vector pSinRep5. Both constructs were tagged with enhanced green fluorescent protein (EGFP) at the N terminus. Linearized DNA was used to produce capped mRNA that lacked the structural components of the virus; these were generated separately in a second transcription procedure with the helper virus plasmid (pDH). Construct and helper mRNAs were transfected into baby hamster kidney cells to generate replication-defective pseudovirions. Twenty-four hours later, the conditioned medium containing viral particles was collected for infection of experimental cells. Three different preparations were generated: SIN-EGFP, SIN-EGFP-PLD1, and SIN-EGFP-PLD1-K898R.

Primary cell culture. Primary hippocampal neuronal cultures were prepared as described previously (Rogove and Tsirka, 1998). Briefly, hippocampi from embryonic day 17–19 mouse embryos were dissected and gently trypsinized (0.25% trypsin in HBSS) at 37°C for 15 min and then triturated to form single-cell suspensions. The cells were plated onto poly-γ-lysine- precoated tissue culture plates in Neurobasal medium with B27 supplements, 25 μM glutamate, 0.5 mM t-glutamine, and 10 μg/ml gentamycin sulfate. The medium was changed 3 h after the initial plating, and the glutamate was removed after 4 d in culture. After 7–10 d in culture, the neurons were infected with Sindbis pseudovirions for 10 h. SIN-EGFP served as the negative control for viral infection.

Determination of length of neurites. To measure neurite length, dissociated hippocampal neurons from C57BL/6 (wild type) and tPA−/− mice were plated on 18-mm-round coverslips at a density of 104 cells per coverslip. After 2 d in culture, the neurons were infected with Sindbis pseudovirions for 4 h, washed with Neurobasal medium, and incubated in regular culture medium overnight. Twenty-four hours later, cells were fixed in 4% paraformaldehyde/4% sucrose in PBS and mounted with VECTASHIELD HardSet mounting medium (Vector Laboratories, Burlingame, CA) for fluorescent microscopic analysis. The sections were examined using a Nikon (Tokyo, Japan) PCM 2000 confocal microscope. The images were captured, and neurite length was measured using SPOT RT software (SPOT Diagnostic Instruments, Sterling Heights, MI). A total of 60 neurons per group were analyzed by an observer blinded to the experimental treatment.

Quantitative Western blot. Virus-infected neurons were collected in PBS containing protease inhibitor mixture (Sigma, St. Louis, MO) and lysed by brief sonication. Total protein concentration was measured using the Bradford detergent-compatible assay (Bio-Rad, Hercules, CA).

Equal amounts (4 μg) of protein from each sample were separated on an 8% SDS-polyacrylamide gel, transferred onto polyvinylidene difluoride membrane, blocked with 5% nonfat dry milk in PBS/0.1% Tween 20 (PBS-T), incubated with anti-PLD1 antibody (affinity-purified polyclonal; 1:3000 dilution) (Zhang et al., 2004) overnight in PBS-T/5% bovine serum albumin, and visualized using Alexa Fluor-488-conjugated secondary antibody (1:1000 dilution; Molecular Probes, Eugene, OR). Fluorescence was detected by a FluorImager (Molecular Devices, Menlo Park, CA) and quantified using ImageQuant software (Amersham Biosciences, Sunnyvale, CA). Anti-actin (mouse monoclonal, 1:1500; ICN Biomedicals, Shelton, CT) was used to confirm equal loading of proteins.

tPA secretion assay. After infection with Sindbis virus, hippocampal neurons were washed and incubated with Neurobasal medium for 1 h. Some neurons were treated with 0.5% 1-butanol or 0.5% 3-butanol in Neurobasal medium for 1 h. Later, neurons were washed with Tyrode’s buffer [pH 7.4, consisting of (in mM) 119 NaCl, 5 KCl, 4 CaCl2, 2 MgCl2, 30 glucose, and 20 HEPES]. The cells were then exposed to 50 μM forskolin (Sigma) or 10 μM Ca2+ ionophore A23187 (Sigma) diluted in Tyrode’s buffer. Some neurons were additionally treated with 0.5% 1-butanol or 0.5% 3-butanol. The supernatant was collected at different time intervals, and the tPA concentration was measured by ELISA using an anti-mouse tPA antibody (monoclonal, 1:12,500; Molecular Innovations, Southfield, MI). The secreted tPA amount was calculated and normalized to total protein concentration.

Animal preparation and surgery. Animals were maintained in the Stony Brook Department of Laboratory Animal Research. All procedures followed guidelines set by the National Institutes of Health and were approved by Stony Brook University.

Intra-amygdaloid kainic acid (KA) injection was performed on adult male wild-type and tPA−/− mice, age matched and weighing ~20 g, as described previously (Niquet et al., 1993; Wu et al., 2000). Mice were given intraperitoneal injections of atropine (0.6 mg/kg body weight), anesthetized deeply with 2.5% avertin (0.02 ml/g body weight), placed in a stereotaxic apparatus, and given a unilateral injection of 1.5 μmol of KA (Sigma) in 0.3 μl of PBS into the amygdala. The coordinates of the injection were as follows: bregma, −1.6 mm; mediolateral, 3.3 mm; dorsoventral, 4.5 mm (Franklin and Paxinos, 1997). KA was delivered over 1 min. After the delivery, the injection needle remained at the above coordinates for another 5 min to prevent reflux of fluid. After KA injection, a mini-osmotic pump (Alzet model 1007D; Durect, Cupertino, CA) containing 100 μl of Sindbis virus suspension was placed subcutaneously in the back of the animal. A brain-infusion cannula connected to the pump was positioned at coordinates bregma −1.8 mm, mediolateral +1.1 mm, and dorsoventral 2.5 mm to deliver the virus near the dentate gyrus (DG) of the hippocampus. The infusion rate was 0.5 μl/h. The pump was allowed to infuse the designated solution for 4 or 7 d. SIN-EGFP served as the negative control. Animals that were used for subsequent experiments (n = 8 for each treatment) displayed seizures scored as 2 or 3, based on the scale described below. The seizure severity was quantified using a five-point observer rating scale, as described by Royle et al. (1999): 0 = normal behavior; 1 = rare wet dog shakes (WDS) and rare convulsions affecting the head and extremities; 2 = typical WDS (0.02 ml/g body weight, placed in a stereotaxic apparatus, and given a unilateral injection of 1.5 μmol of KA (Sigma) in 0.3 μl of PBS into the amygdala. The coordinates of the injection were as follows: bregma, −1.6 mm; mediolateral, 3.3 mm; dorsoventral, 4.5 mm (Franklin and Paxinos, 1997). KA was delivered over 1 min. After the delivery, the injection needle remained at the above coordinates for another 5 min to prevent reflux of fluid. After KA injection, a mini-osmotic pump (Alzet model 1007D; Durect, Cupertino, CA) containing 100 μl of Sindbis virus suspension was placed subcutaneously in the back of the animal. A brain-infusion cannula connected to the pump was positioned at coordinates bregma −1.8 mm, mediolateral +1.1 mm, and dorsoventral 2.5 mm to deliver the virus near the dentate gyrus (DG) of the hippocampus. The infusion rate was 0.5 μl/h. The pump was allowed to infuse the designated solution for 4 or 7 d. SIN-EGFP served as the negative control. Animals that were used for subsequent experiments (n = 8 for each treatment) displayed seizures scored as 2 or 3, based on the scale described below. The seizure severity was quantified using a five-point observer rating scale, as described by Royle et al. (1999): 0 = normal behavior; 1 = rare wet dog shakes (WDS) and rare convulsions affecting the head and extremities; 2 = typical WDS; 3 = frequent WDS and convulsions affecting the head and extremities (no rearing); 4 = frequent head and extremities convulsions with appearance of generalized tonic–clonic seizures usually starting between 60 and 90 min after KA administration with rearing; 5 = continuous, generalized limbic seizures and death within 3 h. No recurrent seizures were evident in the mice beyond the first day after the KA injection. Animals were killed 4, 7, or 15 d after KA injection.

Histochecmy and immunofluorescent microscopy. Animals were perfused transcardially with 0.2% sodium sulfide, after which their brains were removed and freshly frozen. Coronal brain sections (30 μm) at the level of the hippocampus were prepared on a cryostat at −15°C (Leica CM 1900; Leica Microsystems, Bannockburn, IL). MFS were stained according to a modified Timm silver staining method (Holm and Geneser, 1991). GAP-43 (mouse monoclonal, 1:500; Sigma) staining was performed to show newly formed sprouts, detected with cyanine 3 (Cy3)- conjugated secondary antibodies (1:1000; Jackson ImmunoResearch, West Grove, PA). For visualization of the general histology in the hippocampi, sections were stained for 30 min in 0.5% cresyl violet solution. To trace the expression of EGFP-tagged proteins in the brain, sections were fixed with 4% paraformaldehyde/4% sucrose in PBS and then mounted with Vectashield mounting medium (Vector Laboratories) for fluorescent microscopic analysis. To confirm neuronal expression of...
these transgenes, the same brain sections were also stained with primary antibodies against a neuronal marker protein, neuron-specific nuclear protein (NeuN; mouse monoclonal, 1:500; Chemicon, Temecula, CA) and then detected with Cy3-conjugated secondary antibodies (1:1000; Jackson ImmunoResearch). The sections were examined using a Nikon PCM 2000 confocal microscope. Images were captured by an observer blinded to the experimental treatment. Quantitation of Timm stain was performed using Scion Image software (Scion Corporation, Frederick, MD). Timm granules were measured in the DG and CA3 regions using the Scion software and normalized by surface area (and length of the DG), as described by Zheng et al. (1998).

In situ zymography. Coronal brain sections (30 μm) were overlaid with a mixture consisting of 1% low-melting point agarose, 1 ml/ml plasminogen, 1 mM amiloride (a selective urokinase inhibitor), 0.1 mM Tris-Cl, pH 7.5, and 2.5% nonfat dry milk. The sections were overlaid onto the overlay and then incubated at 37°C in a humidified chamber. tPA activity was visualized as degradation of casein (a clearing of the overlay) and then incubated at 37°C in a humidified chamber. tPA secretion from neurons is potentiated by wild-type PLD1 (Zhang et al., 2004), but the expression of transfected PLD1 was increased dramatically as detected by quantitative Western blotting (Fig. 1). Hippocampal neurons do express PLD1 (Zhang et al., 2004), but the low-abundance endogenous protein was not visualized with the short exposure times determined to be optimal for detecting the overexpressed proteins.

PLD1 is a highly regulated enzyme, typically exhibiting little to no activity in nonstimulated cells and dramatic activation in stimulated cells. To explore whether PLD1 overexpression alters regulated tPA secretion, we first examined the basal levels of tPA secretion from unstimulated neurons expressing EGFP, EGFP-PLD1, or EGFP-PLD1(K898R). No significant difference was observed, indicating that high expression of neither PLD1 nor PLD1(K898R) altered tPA secretion via toxic or nonspecific mechanisms. Stimulation of cultured rat hippocampal neurons by 50 μM forskolin has previously been reported to induce tPA secretion, which is followed by formation of varicosities and axonal elongation (Baranes et al., 1998). After forskolin stimulation, the secretion of tPA from neurons expressing EGFP-PLD1 increased twofold compared with cells expressing just EGFP (Fig. 2a), whereas those expressing catalytically inactive PLD1 exhibited a small decrease. These results suggest that PLD1 activation is a rate-limiting event in forskolin-triggered tPA secretion by neurons, although it may underestimate the role of PLD1 because forskolin is not a traditional PLD stimulator (Mamoo et al., 1999). The catalytically inactive (dominant-negative) approach was further supported by pharmacological inhibition of PLD1 using 1-butanol, a primary alcohol that inhibits PLD signaling by competitively diverting the production of phosphatidic acid to phosphatidyl-butanol (McDermott et al., 2004). PLD1-enhanced tPA secretion as stimulated by forskolin was attenuated in the presence of 0.5% 1-butanol but not completely ablated (Fig. 2a). This partial decrease was likely because of the relatively low amount of 1-butanol used, because PLD1 activity is not totally inhibited at this concentration (Skippen et al., 2002). Higher concentrations of 1-butanol that could fully block PLD1 activity were not used, because they can elicit toxicity (Skippen et al., 2002). In contrast, 0.5% 3-butanol, a tertiary alcohol that does not serve as a substrate for the transphosphatidylation reaction catalyzed by PLD, was less able to inhibit tPA release (Fig. 2a). Even greater tPA release was observed for neurons stimulated by 10 μM Ca2+ ionophore A23187, which is a potent activator of PLD1 (Siddiqi et al., 2000), and this increase was again inhibited to a greater extent by 1-butanol than by 3-butanol (Fig. 2b). Finally, control neurons also exhibited a decrease in ionophore-triggered tPA secretion in the presence of 1-butanol (Fig. 2c), suggesting that endogenous neuronal PLD1 facilitates tPA release. Together, these data indicate that in cultured primary hippocampal neurons, PLD1 mediates tPA secretion through mechanisms dependent on its catalytic activity.

**Promotion of neurite extension by PLD1 overexpression**

We next set out to examine whether PLD1-altered neurite extension. Secretion of tPA has been shown to be essential for neurite sprouting both in vivo and in vitro (García-Rocha et al., 1994; Wu et al., 2000; Parmar et al., 2002); therefore, proteins that modulate tPA secretion could influence neurite extension as well. We measured the length of neurites of...
individual wild-type and tPA−/− neurons from low-density cell cultures infected with PLD1-expressing and control virions (Fig. 3). The average neurite length of wild-type neurons overexpressing PLD1 was 69 ± 21 μm, which was significantly longer than that of EGFP-expressing control cells (53 ± 17 μm). The effect of PLD1 was activity dependent, because no increase in neurite length was observed in cells infected with EGFP-PLD1(K898R) virus (53 ± 17 μm). EGFP-PLD1(K898R) did not function effectively as a dominant-negative isoform in this assay, potentially because the relatively small amount of inhibition of tPA release that occurred (Fig. 2a) was not sufficient to lead to a detectable suppression of neurite extension. Again, it should be noted that this assay probably underestimates the role of PLD1, because no deliberate stimulation of the enzyme took place under the culture conditions. On the other hand, overexpression of PLD1 in tPA−/− neurons did not affect neurite length compared with control cells (Fig. 3). The average neurite length of wild-type neurons overexpressing PLD1 was 69 μm, which was significantly longer than that of EGFP-expressing control cells (51 μm). The effect of PLD1 was activity dependent, because no increase in neurite length was observed in cells infected with EGFP-PLD1(K898R) virus (53 μm). EGFP-PLD1(K898R) did not function effectively as a dominant-negative isoform in this assay, potentially because the relatively small amount of inhibition of tPA release that occurred (Fig. 2a) was not sufficient to lead to a detectable suppression of neurite extension. Again, it should be noted that this assay probably underestimates the role of PLD1, because no deliberate stimulation of the enzyme took place under the culture conditions. On the other hand, overexpression of PLD1 in tPA−/− neurons did not affect neurite length compared with control cells (Fig. 3a), demonstrating that tPA functions downstream of PLD1 to promote neurite growth and that PLD1 functions via a tPA-dependent pathway.

Marked changes in tPA secretion and MF outgrowth with neuronal overexpression of PLD1 or PLD1(K898R) in the mouse hippocampus

It has been shown previously that extracellular tPA activity increases in the hippocampus after membrane depolarization, presumably as a consequence of being secreted (Gualandris et al.,
Secreted tPA participates in hippocampal MF growth and remodeling via mechanisms dependent on and independent of its enzymatic activity (Wu et al., 2000). We therefore set out to investigate whether PLD1 contributes to neuronal tPA secretion and subsequent MF sprouting in the mouse hippocampus. Successful gene transfer into neurons via injection of Sindbis virions and subsequent MF sprouting in the mouse hippocampus. Successful gene transfer into neurons via injection of Sindbis virions into different regions of the mouse brain, including the hippocampus, has been reported (Agapov et al., 1998; Chen et al., 1996). Secreted tPA participates in hippocampal MF growth and remodeling via mechanisms dependent on and independent of its enzymatic activity (Wu et al., 2000). We therefore set out to investigate whether PLD1 contributes to neuronal tPA secretion and subsequent MF sprouting in the mouse hippocampus. Successful gene transfer into neurons via injection of Sindbis virions into different regions of the mouse brain, including the hippocampus, has been reported (Agapov et al., 1998; Chen et al., 2000; D’Apuzzo et al., 2001; Takahashi et al., 2003).

We further optimized delivery of PLD1 Sindbis virus into the mouse hippocampus by using micro-osmotic pumps. Figure 4b illustrates expression of recombinant EGFP-PLD1 [or PLD1(K898R)] in the DG on day 15 after the start of infusion. Infection was restricted to neurons within the virus-infused area. As judged from cell morphology based on cresyl violet stain (Figs. 4a, 5a) and NeuN stain (Fig. 4b), no significant cell toxicity was discernible after viral infection, at least up to days 15 after infection. In situ tPA activity and MF outgrowth were followed over the 15 d time course after viral infection. Although the results in Figure 3 suggest that subtle alterations in MF morphology might be observed even in control mice, our previous findings indicate that tPA plays a more overt role in mice subjected to epileptic stimulation (Wu et al., 2000), and thus we examined both control and kainate-injected groups of mice. Kainate, a glutamate analog, stimulates tPA release and epileptic seizures and is well known as a PLD activator in the CNS (Holler et al., 1993; Pellegrini-Giampietro et al., 1996). The injection of excitotoxins has been shown to stimulate the quick secretion of tPA locally; in this model, kainate is delivered distally (amygdala) to the area where MF sprouting and tPA secretion are visualized (hippocampus). Therefore a delay in monitoring of MF sprouting and tPA activity is necessary (Niquet et al., 1993). The punctate pattern of GAP-43 stain confirmed the presence of newly formed MF sprouts in the hippocampus at day 15 after intra-amygdaloid kainate injection (Fig. 5b).

Kainate injection into SIN-EGFP-infused wild-type mice elicited sprouting by day 15 on the ipsilateral side of the supragranular region of the DG but not on the contralateral side (Figs. 6a–c, 7a,b). The changes observed were consistent with the extent of sprouting we and others have reported previously (Represa et al., 1987; Niquet et al., 1993; Wu et al., 2000). In contrast, marked increases in sprouting were observed on the ipsilateral side in kainate-injected wild-type mice infused with SIN-EGFP-PLD1 (Fig. 6d); exaggerated sprouts were evident in both the supragranular region of the dentate (Fig. 7c, arrows) and the strata infrapyramidale (Fig. 6e, asterisks) and oriens of the CA3 region (Figs. 6e, 7d, arrows), especially in the stratum infrapyramidale, indicating the presence of robust axonal sprouting (quantitation of changes listed in Table 1). In a previous report (Zhang et al., 2004), we showed that PLD1 is upregulated after kainate delivery, and although the levels of increase achieved by PLD1 overexpression are higher than those achieved by the kainate injection, they point to a role of PLD1 in promoting neurite outgrowth.

Conversely, in wild-type mice infused with SIN-EGFP-PLD1(K898R), there were locally distinct patterns of inhibited MF sprouting (Fig. 6g): in the CA3 region; the sprouts were mostly diminished, most notably in the stratum infrapyramidale (Figs. 6h, arrows, 7f, red arrows) (quantitation of changes is listed in Table 1), whereas in the dentate, the sprouts were blunted (Fig. 7e, red arrows) and formed aggregates of Timm-stained granules along the border between the supragranular region and the molecular layer (Fig. 7e, blue arrows). This phenotype is comparable with the pattern of MF sprouting described for tPA−/− mice (Wu et al., 2000), as shown in Figure 7, g and h, in which EGFP was delivered in kainate-stimulated tPA−/− mice.

To explore whether the changes observed in the mice correlated with decreased tPA release, we performed in situ zymographic assays. In the unstimulated hippocampus of wild-type
mice, tPA activity is concentrated along the MF pathway: the CA3 area and the hilus (Tirskia et al., 1995; Salle’s and Strickland, 2002; Siao et al., 2002). With epileptic stimulation, tPA activity increases moderately along the MF pathway on the ipsilateral side, as seen in mice infected with SIN-EGFP day 7 after kainate injection (Fig. 6a, blue area outlined by arrows). With EGFP-PLD1 infusion, up-regulation of secreted tPA activity was observed in the DG and CA3 on the stimulated side (Fig. 8c, arrows) compared with either the contralateral hippocampus of the same mouse (Fig. 8d, arrows) or the ipsilateral side of the kainate-injected, SIN-EGFP-infected hippocampus (Fig. 8a). In contrast, decreased tPA activity was detectable in the hippocampus infected with SIN-EGFP-PLD1(K898R) (Fig. 8e) compared with the contralateral side of the same animal (Fig. 8f, arrows) or either side of the control animals (Fig. 8a).

Changes in MF growth were not detected in any of the experimental groups at day 7. Conversely, levels of secreted tPA were indistinguishable at day 15 (and change in neither MF growth nor secreted tPA activity was demonstrable at day 4). This separation in the time course of tPA secretion (day 7) and MF growth (day 15) is consistent with the hypothesis that tPA secretion precedes observable neurite growth.

To examine whether the effect of PLD1 expression on MF extension proceeds through a tPA-dependent pathway, we examined the outcome in tPA−/− mice. A previous study from our group had demonstrated that kainate-stimulated tPA−/− mice exhibit diminished and aberrant MF sprouting because of deficits in the process of ECM remodeling (Wu et al., 2000).

Kainate-treated tPA−/− mice expressing high levels of PLD1 displayed blunted, distorted sprouts (Fig. 6d–f and data not shown) and a dense laminar band between the supragranular and molecular layers, comparable with that observed in tPA−/− mice receiving control virion infusion (Fig. 7g, red and blue arrows). In addition, decreased neurite growth in the stratum oriens of the CA3 area (Fig. 6e′, arrows) was evident in these mice compared with wild-type mice treated similarly (Fig. 6e, arrows). The different outcomes in MF outgrowth for the PLD1-overexpressing wild-type and tPA−/− mice demonstrate that the effect of PLD1 on MF growth is mediated through the action of tPA (i.e., lack of tPA leads to disorganized sprouting regardless of the PLD1 expression level). Expression of inactive PLD1 in the tPA−/− hippocampus resulted in formation of intensely Timm-positive clusters in the DG (Fig. 6g′ and data not shown) and a marked decrease in MF sprouts in the stratum infrapyramidal (Fig. 6h′, arrows), similar to the pattern observed for wild-type mice treated identically. This phenotype confirms and extends our cell culture and in vivo data. We conclude that PLD1 functions upstream of tPA in the regulation of neurite growth.

In summary, our in vivo studies demonstrate that there is a positive correlation between levels of neuronal PLD1 and both tPA secretion and MF outgrowth. Higher expression of active PLD1 in DG neurons of the wild-type mice elicits more prominent MF sprouting in the DG locally and in the spatially removed CA3 region. In contrast, mice expressing the inactive PLD1 are characterized by aberrantly sprouted blunt MF in the DG and fewer sprouts in CA3.

Discussion

Extracellular tPA makes a major contribution to neuroplasticity by remodeling cell–cell and cell–matrix contacts in the path of the advancing growth cone (Krystosek and Seeds, 1981; Pittman, 1985; Wu et al., 2000). The active protease is synthesized and stored in vesicles in neurons. Secretion of tPA can be triggered rapidly by increased neuronal activity. Regulated tPA release has been demonstrated in chromaffin cells (Parmer et al., 1997, 2000; Lochner et al., 1998). In these cells, tPA is presumably targeted to catecholamine storage vesicles and coreleases with catecholamines after stimulation, based on subcellular fractionation methods and secretagogue-release assays. Lochner et al. (1998) generated direct evidence for the vesicular localization of tPA in rat pheochromocytoma PC12 cells. A tPA/EGFP hybrid protein was expressed in PC12 cells, and its subcellular distribution and dynamics were monitored through real-time imaging of the green fluorescent labeling. They found that tPA/EGFP was packed in intracellular vesicles and transported toward the growth cone.
that PLD is involved in both the secretory pathway and neurite activity (Frohman et al., 1999). Other researchers have shown protein kinase C (PKC) activity. PKC is a potent activator of PLD.

PC12 cells are affected by modulation of protein kinase A and tPA and the induction of short neurite growth by differentiating conditioned media. Leprince et al. (1996) reported that release of endogenous tPA was detected on the side with elevated neuronal expression of active PLD1 compared with the contralateral hippocampal of the same mouse. The blue area outlined by arrows indicates the presence of tPA activity. An enhanced level of secreted tPA was detected on the side with elevated neuronal expression of active PLD1 compared with the contralateral hippocampus of the same mouse. The blue area outlined by arrows indicates the presence of tPA activity. An enhanced level of secreted tPA was detected on the side with elevated neuronal expression of active PLD1 compared with the contralateral hippocampus of the same mouse.

For PLD to directly influence tPA secretion, it should be present in the cell that releases the tPA. In the CNS, tPA is made by two cell types, neurons and microglia (Strickland et al., 1996). Given that we found preferential expression of PLD1 by neurons and PLD2 by astrocytes (Zhang et al., 2004), we thus focused on the potential role of PLD1 in tPA secretion from neurons.

In cultured mouse hippocampal neurons, we demonstrated growth. For example, PLD1 has been clearly linked to regulation of secretion and secretory granule exocytosis in a variety of cell types, including neurons (Chen et al., 1997; Vitale et al., 2001; Choi et al., 2002). Vitale et al. (2001) demonstrated that, in neuroendocrine cells, overexpressed PLD1 increases secretagogue-stimulated exocytosis, whereas catalytically inactive PLD1 inhibits it. Similarly, Humeau et al. (2001) described that injection of catalytically inactive PLD1 protein inhibits acetylcholine release by >90% in Aplysia neurons, suggesting that PLD1 regulates a rate-limiting step of exocytosis in that setting. In most cases, the catalytically inactive PLD mutant is able to partially inhibit PLD-dependent biological events (Vitale et al., 2001), presumably by competing with endogenous PLD for inclusion into the protein complexes that mediate the process. This effect is obtained when high levels of overexpression of the inactive allele are achieved. Although the catalytically inactive protein is frequently not a very effective dominant negative, several other approaches have been used here and elsewhere in model systems to examine the role of the endogenous protein, including pharmacological inhibitors (ceramide, alcohol) and overexpression of a PLD activator, ARF6, to stimulate endogenous PLD1 (or inhibit it, with use of the inactive ARF6 mutant allele) (Vitale et al., 2002). Although all of these approaches have caveats, results supporting a role for endogenous PLD1 in regulated exocytosis were obtained in each case.

For PLD to directly influence tPA secretion, it should be present in the cell that releases the tPA. In the CNS, tPA is made by two cell types, neurons and microglia (Strickland et al., 1996). Given that we found preferential expression of PLD1 by neurons and PLD2 by astrocytes (Zhang et al., 2004), we thus focused on the potential role of PLD1 in tPA secretion from neurons.

In cultured mouse hippocampal neurons, we demonstrated growth. For example, PLD1 has been clearly linked to regulation of secretion and secretory granule exocytosis in a variety of cell types, including neurons (Chen et al., 1997; Vitale et al., 2001; Choi et al., 2002). Vitale et al. (2001) demonstrated that, in neuroendocrine cells, overexpressed PLD1 increases secretagogue-stimulated exocytosis, whereas catalytically inactive PLD1 inhibits it. Similarly, Humeau et al. (2001) described that injection of catalytically inactive PLD1 protein inhibits acetylcholine release by >90% in Aplysia neurons, suggesting that PLD1 regulates a rate-limiting step of exocytosis in that setting. In most cases, the catalytically inactive PLD mutant is able to partially inhibit PLD-dependent biological events (Vitale et al., 2001), presumably by competing with endogenous PLD for inclusion into the protein complexes that mediate the process. This effect is obtained when high levels of overexpression of the inactive allele are achieved. Although the catalytically inactive protein is frequently not a very effective dominant negative, several other approaches have been used here and elsewhere in model systems to examine the role of the endogenous protein, including pharmacological inhibitors (ceramide, alcohol) and overexpression of a PLD activator, ARF6, to stimulate endogenous PLD1 (or inhibit it, with use of the inactive ARF6 mutant allele) (Vitale et al., 2002). Although all of these approaches have caveats, results supporting a role for endogenous PLD1 in regulated exocytosis were obtained in each case. Cell types

Table 1. Quantification of MF outgrowth in mice expressing the wild-type or mutant PLD1 allele

<table>
<thead>
<tr>
<th>Hippocampal subfield</th>
<th>Treatment</th>
<th>Timm index</th>
</tr>
</thead>
<tbody>
<tr>
<td>DG</td>
<td>EGFP</td>
<td>99.57 ± 0.46</td>
</tr>
<tr>
<td></td>
<td>EGFP-PLD1</td>
<td>166.32 ± 0.62*</td>
</tr>
<tr>
<td></td>
<td>EGFP-PLD1(K898R)</td>
<td>107.41 ± 13.99</td>
</tr>
<tr>
<td>CA3</td>
<td>EGFP</td>
<td>110.3 ± 10.07</td>
</tr>
<tr>
<td></td>
<td>EGFP-PLD1</td>
<td>163.86 ± 11.45*</td>
</tr>
<tr>
<td></td>
<td>EGFP-PLD1(K898R)</td>
<td>68.43 ± 7.96*</td>
</tr>
</tbody>
</table>

Hippocampal MFs in wild-type mice were assessed by Timm stain as shown in Figures 6 and 7. Timm granules were measured in the DG and CA3 regions using the Scion software and normalized by surface area (and length of the DG), as described by Zheng et al. (1998). Results are presented as mean ± SD (n = 5 for each group). Data from the EGFP-PLD1 and EGFP-PLD1(K898R) group are both compared with the EGFP control group. *p < 0.01.

Figure 7. Gain- and loss-of-function changes, respectively, in DG and CA3 MF sprouting at day 15 as a consequence of CNS overexpression of wild-type and catalytically inactive PLD1. Higher-magnification images of selected regions in Figure 6 are shown. MF sprouts and boutons are indicated by red arrows. Blue arrows denote the abnormal laminar band of Timm staining observed in wild-type mice expressing inactive PLD1 and in tPA−/− mice at the border separating the molecular and granular cell layers.

Figure 8. Regulation of tPA secretion by PLD1 as a consequence of kainate challenge at day 7. In situ zymography was performed on 30 μm coronal brain sections from wild-type mice killed at day 7 after unilateral viral infusion and kainate injection (labeled as ipsilateral; the untreated side is marked as contralateral). The grayscale image was converted to pseudocolor for better visualization of the zymography images, and the intensity scale bar is shown on the right. The blue area outlined by arrows indicates the presence of tPA activity. An enhanced level of secreted tPA was detected on the side with elevated neuronal expression of active PLD1 (e, arrows) compared with either the contralateral hippocampus of the same mouse (d, arrows) or that of the SIN-EGFP-infused hippocampus (a, arrows). In contrast, tPA activity was diminished in the hippocampus expressing inactive PLD1 (f, arrows) compared with either the contralateral side (d, arrows indicating basal tPA activity) or control animals (a, arrows).
that PLD1 substantially enhanced tPA secretion induced by either forskolin or Ca2+ ionophore in an activity-dependent manner. This effect was primarily attenuated by the addition of 1-butanol, which also suppressed stimulated tPA release from control neurons not expressing the exogenous PLD1 gene, suggesting an involvement of endogenous PLD in tPA release. These findings indicate that neuronal PLD1 is a vital component in the pathway controlling tPA secretion. The facilitated tPA release was accompanied by exaggerated neurite extension, suggesting a physiological relevance to the regulation of tPA secretion by PLD1, and this was confirmed in the in vivo setting using a model for epilepsy well known to elicit (MF) neurite extension in the DG.

Several mechanisms have been proposed by us and others regarding how PLD might regulate secretory machinery and/or neurite outgrowth. First, PA, which is generated by PLD at the plasma membrane, is a multifunctional lipid that can be further metabolized to other important signaling lipids such as diacylglycerol and lysophosphatidic acid. In addition, it can activate other signaling enzymes (Honda et al., 1999), facilitate membrane vesicle fusion events (Vitale et al., 2002), or serve as a lipid anchor for membrane-associated proteins (Rizzo et al., 2000). Second, PLD is thought to promote sustained activation of PKC through the generation of PA and possibly diacylglycerides, both of which stimulate PKC. PLD could thus promote secretion, because activation of PKC along with an increase in cytosolic free calcium are essential signals for secretion in many cell types, including hippocampal neurons (Ruehr et al., 1997). Third, a mechanism that links neurite outgrowth and vesicle trafficking is the idea that to extend neurites, cells need to synthesize, reorganize, and transport phospholipids to the plasma membrane. PC, the substrate of PLD, is the most abundant phospholipid in mammalian biological membranes. Thus, PLD might be required for replenishing lipid components of the plasma membrane during neuroplastic remodeling.

How would PLD become activated in this setting? It has been reported that stimulation of metabotropic glutamate receptors by glutamate results in increased PLD activity in the rat hippocampus (Holler et al., 1993; Attucci et al., 2001). Glutamate is the primary amino acid neurotransmitter in the hippocampal MF pathway (Henze et al., 2000). tPA is known to mediate MF sprouting (Wu et al., 2000). Therefore, it is possible that after stimulation, increased levels of glutamate would activate PLD, which in turn would promote tPA release, leading to MF sprouting.

In this study, we describe a novel regulatory mechanism underlying neuronal tPA secretion during axonal sprouting that could be manipulated to modify the course of neurite growth and subsequent pathophysiological changes.

References


